Recombinant multi-species SETD2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SETD2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Huntington's disease (HD), a neurodegenerative disorder characterized by loss of striatal neurons, is caused by an expansion of a polyglutamine tract in the HD protein huntingtin. This gene encodes a protein belonging to a class of huntingtin interacting proteins characterized by WW motifs. This protein is a histone methyltransferase that is specific for lysine-36 of histone H3, and methylation of this residue is associated with active chromatin. This protein also contains a novel transcriptional activation domain and has been found associated with hyperphosphorylated RNA polymerase II. [provided by RefSeq, Aug 2008]
The Alternative Names of target: 4921524K10Rik,HBP231,HIF-1,HIP-1,HSPC069,HYPB,Histone-lysine N-methyltransferase SETD2,Huntingtin yeast partner B,Huntingtin-interacting protein 1 (HIP-1),Huntingtin-interacting protein B,KMT3A,LLS,Lysine N-methyltransferase 3A,MRD70,Protein-lysine N-methyltransferase SETD2,RAPAS,SET domain-containing protein 2 (hSET2),SET2,SETD2,Setd2,p231HBP

Target products collectionGo to SETD2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T73551-Ag-1/ GM-Tg-hg-T73551-Ag-2 Human SETD2 protein Human
GM-Tg-rg-T73551-Ag-1/ GM-Tg-rg-T73551-Ag-2 Rat SETD2 protein Rat
GM-Tg-mg-T73551-Ag-1/ GM-Tg-mg-T73551-Ag-2 Mouse SETD2 protein Mouse
GM-Tg-cynog-T73551-Ag-1/ GM-Tg-cynog-T73551-Ag-2 Cynomolgus/Rhesus macaque SETD2 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T73551-Ag-1/ GM-Tg-felg-T73551-Ag-2 Feline SETD2 protein Feline
GM-Tg-cang-T73551-Ag-1/ GM-Tg-cang-T73551-Ag-2 Canine SETD2 protein Canine
GM-Tg-bovg-T73551-Ag-1/ GM-Tg-bovg-T73551-Ag-2 Bovine SETD2 protein Bovine
GM-Tg-equg-T73551-Ag-1/ GM-Tg-equg-T73551-Ag-2 Equine SETD2 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T73551-Ag-1/ GM-Tg-hg-T73551-Ag-2; GM-Tg-rg-T73551-Ag-1/ GM-Tg-rg-T73551-Ag-2;
GM-Tg-mg-T73551-Ag-1/ GM-Tg-mg-T73551-Ag-2; GM-Tg-cynog-T73551-Ag-1/ GM-Tg-cynog-T73551-Ag-2;
GM-Tg-felg-T73551-Ag-1/ GM-Tg-felg-T73551-Ag-2; GM-Tg-cang-T73551-Ag-1/ GM-Tg-cang-T73551-Ag-2;
GM-Tg-bovg-T73551-Ag-1/ GM-Tg-bovg-T73551-Ag-2; GM-Tg-equg-T73551-Ag-1/ GM-Tg-equg-T73551-Ag-2
Products Name SETD2 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name SETD2
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SETD2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.